Prevalence of vascular disruption anomalies and association with young maternal age: A EUROCAT study to compare the United Kingdom with other European countries

[Corrections added after online publication, 16 November 2022: The last name of Dr. Jennifer M. Broughan was incorrectly spelled in the initial publication. It has been corrected.]Background: Younger mothers are at a greater risk of having a pregnancy with gastroschisis and the risk is higher in the United Kingdom than other European countries. Gastroschisis is thought to be a vascular disruption anomaly and the aim of this study was to analyze the prevalence of other possible vascular disruption anomalies to determine whether both the younger maternal age and the UK associations also occur with these anomalies. Methods: All pregnancies with anomalies considered potentially due to vascular disruption from January 1, 2005 to December 31, 2017 from 26 European population-based congenital anomaly registries who were members of EUROCAT were analyzed. Multilevel models were used to allow for differences between registries when analyzing associations with maternal age, year of birth and whether the registry was in the United Kingdom. Results: There were 5,220 cases with potential vascular disruption anomalies, excluding chromosomal and genetic conditions, with a prevalence of 8.85 per 10,000 births in the United Kingdom and 5.44 in the other European countries. The prevalence per 10,000 births of gastroschisis (4.45 vs. 1.56) and congenital constriction bands (0.83 vs. 0.42) was significantly higher in the United Kingdom, even after adjusting for maternal age. However, transverse limb reduction defects had a similar prevalence (2.16 vs. 2.14 per 10,000). The expected increased prevalence in younger mothers was observed for vascular disruption anomalies overall and for the individual anomalies: gastroschisis and congenital constriction bands. Conclusion: Vascular disruption anomalies that had an increased risk for younger mothers (such as gastroschisis) had a higher maternal age standardized prevalence in the United Kingdom, while vascular disruption anomalies with weaker associations with younger mothers (such as transverse limb reduction defects) did not have an increased prevalence in the United Kingdom, which may indicate a different etiology for these anomalies.European Commissioninfo:eu-repo/semantics/publishedVersio

Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study

This study investigated the risk of congenital heart defects (CHD) and other congenital anomalies (CA) associated with first trimester use of macrolide antibiotics (mainly erythromycin, spiramycin, clarithromycin and azithromycin) and lincosamides (clindamycin) using a case-malformed control design. Data included 145,936 babies with a CA diagnosis (livebirths, stillbirths and terminations of pregnancy for CA) from 15 population-based EUROCAT registries in 13 European countries, covering 9 million births 1995-2012. Cases were babies with CHD, anencephaly, orofacial clefts, genital and limb reduction anomalies associated with antibiotic exposure in the literature. Controls were babies with other CA or genetic conditions. Main outcomes were odds ratios adjusted (AOR) for maternal age and registry, with 95% Confidence Intervals (95%CI). Macrolide and lincosamide exposure was recorded for 307 and 28 cases, 72 and 4 non-genetic controls, 57 and 7 genetic controls, respectively. AOR for CHD was not significantly raised (AOR 0.94, 95%CI: 0.70 - 1.26 vs non-genetic controls; AOR 1.01, 95%CI: 0.73 - 1.41 vs genetic controls), nor significantly raised for any specific macrolide. The risk of atrioventricular septal defect was significantly raised with exposure to any macrolide (AOR 2.98; 95%CI: 1.48 - 6.01), erythromycin (AOR 3.68, 95%CI: 1.28 - 10.61), and azithromycin (AOR 4.50, 95%CI: 1.30 - 15.58). Erythromycin, clarithromycin, azithromycin, and clindamycin were associated with an increased risk of at least one other CA. Further research is needed on the risk of specific CA associated with macrolide and lincosamide use in the first trimester, particularly relevant for the potential use of azithromycin in the treatment of COVID-19

Juliano Moreira e a Gazeta Medica da Bahia Juliano Moreira and the Gazeta Medica da Bahia

Estudos recentes sobre Juliano Moreira enfatizam sua obra no Rio de Janeiro (1903-1933), mas o objetivo central deste artigo é descrever sua contribuição na Gazeta Medica da Bahia, em período anterior (1893-1903). Descreve a trajetória dessa revista que serviu de veículo para as pesquisas originais da Escola Tropicalista Bahiana. Apresenta a produção de Moreira na Gazeta, em que ele surge como estudioso nas áreas de dermatologia, sifilografia e parasitologia, tendo identificado, pela primeira vez no Brasil, a leishmaniose cutâneo-mucosa. Nessa época ele também se afirma como professor em neuropsiquiatria, passando a realizar estudos clínicos na área, analisar modelos assistenciais e propor mudanças na assistência médica. Destaca a importância de Moreira não só como colaborador da Gazeta durante uma década, mas também como redator, bem como sua atuação como redator principal (1901-1902).<br>Recent studies of Juliano Moreira have emphasized his work in Rio de Janeiro (1903-1933), but the main objective of this article is to describe his contribution to the Gazeta Medica da Bahia in the period before that (1893-1903). It describes the evolution of this magazine, which served as a vehicle for original research of the Bahian Tropicalist School It presents Moreira?s output in the Gazeta, in which he emerges as a student of dermatology, syphilology and parasitology, having identified cutaneous leishmaniasis for the first time in Brazil. At that time, he also consolidates his reputation as a professor in neuropsychiatry, conducting clinical studies in the field, analyzing treatment models and proposing changes in medical treatment. It highlights the importance of Moreira not only as a collaborator on the Gazeta during a decade, but also as an editor, as well as his role as chief editor (1901-1902)

Surveillance of multiple congenital anomalies; searching for new associations

Many human teratogens are associated with a spectrum of congenital anomalies rather than a single defect, and therefore the identification of congenital anomalies occurring together more frequently than expected may improve the detection of teratogens. Thirty-two EUROCAT congenital anomaly registries covering 6,599,765 births provided 123,566 cases with one or more major congenital anomalies (excluding chromosomal and genetic syndromes) for the birth years 2008–2016. The EUROCAT multiple congenital anomaly algorithm identified 8804 cases with two or more major congenital anomalies in different organ systems, that were not recognized as part of a syndrome or sequence. For each pair of anomalies, the odds of a case having both anomalies relative to having only one anomaly was calculated and the p value was estimated using a two-sided Fisher’s exact test. The Benjamini–Hochberg procedure adjusted p values to control the false discovery rate and pairs of anomalies with adjusted p values < 0.05 were identified. A total of 1386 combinations of two anomalies were analyzed. Out of the 31 statistically significant positive associations identified, 20 were found to be known associations or sequences already described in the literature and 11 were considered “potential new associations” by the EUROCAT Coding and Classification Committee. After a review of the literature and a detailed examination of the individual cases with the anomaly pairs, six pairs remained classified as new associations. In summary, systematically searching for congenital anomalies occurring together more frequently than expected using the EUROCAT database is worthwhile and has identified six new associations that merit further investigation.info:eu-repo/semantics/publishedVersio

Epidemiology of septo-optic dysplasia with focus on prevalence and maternal age – a EUROCAT study

Septo-optic nerve dysplasia is a rare congenital anomaly known to be caused by a midline developmental defect in the prosencephalon. The clinical findings are visual impairment, hypopituitarism and developmental delays and severity is related to the extent of the cerebral anomalies in septum pellucidum, optic nerves and hypothalamus. The aim of this study was to report prevalence, associated anomalies, maternal age and other epidemiology factors from a large European population based network of congenital anomaly registries (EUROCAT). Data from 29 full member registries for the years 2005-2014 were included, covering 6.4 million births. There were 99 cases with a diagnosis of septo-optic dysplasia. There was evidence of under-reporting in some registries. If underreporting was assumed to occur in the 14 registries with the lowest prevalences, the overall prevalence in the top 15 registries would be a good estimate of the overall prevalence. It was 2.51 per 100,000 births (95%CI: 1.60-3.58), with clear evidence of heterogeneity; I2=59.9%. If there was no under-reporting the estimated prevalence for all registries would be 2.51/1.35 = 1.9 per 100,000 births with 95% CI approximately (1.2 - 2.6) (The 1.35 adjusts for taking the prevalence of the highest 15 registries). The prevalence of septo-optic dysplasia in Europe is therefore likely to be between 1.9 to 2.5 per 100,000 births. The prevalence was highest for mothers aged 20 to 24 years of age and was significantly higher in UK registries compared with other EUROCAT registries (P = 0.021 in the multilevel model) and the increase was greater for younger mothers in the UK (P=0.027). The majority of septo-optic dysplasia cases were classified as isolated cerebral anomaly (77%) and only two cases had a genetic diagnosis. The anomaly may not be apparent at birth and this is reflected in that 57% of the postnatal diagnoses occurred over 1 month after birth. Septo-optic dysplasia share patterns with gastroschisis and this strengthen the hypothesis of vascular disruption being an aetiological factor for septo-optic dysplasia.JRC.F.1-Health in Societ

Prevalence of vascular disruption anomalies and association with young maternal age: A EUROCAT study to compare the United Kingdom with other European countries

Background: Younger mothers are at a greater risk of having a pregnancy with gastroschisis and the risk is higher in the United Kingdom than other European countries. Gastroschisis is thought to be a vascular disruption anomaly and the aim of this study was to analyze the prevalence of other possible vascular disruption anomalies to determine whether both the younger maternal age and the UK associations also occur with these anomalies. Methods: All pregnancies with anomalies considered potentially due to vascular disruption from January 1, 2005 to December 31, 2017 from 26 European population-based congenital anomaly registries who were members of EUROCAT were analyzed. Multilevel models were used to allow for differences between registries when analyzing associations with maternal age, year of birth and whether the registry was in the United Kingdom. Results: There were 5,220 cases with potential vascular disruption anomalies, excluding chromosomal and genetic conditions, with a prevalence of 8.85 per 10,000 births in the United Kingdom and 5.44 in the other European countries. The prevalence per 10,000 births of gastroschisis (4.45 vs. 1.56) and congenital constriction bands (0.83 vs. 0.42) was significantly higher in the United Kingdom, even after adjusting for maternal age. However, transverse limb reduction defects had a similar prevalence (2.16 vs. 2.14 per 10,000). The expected increased prevalence in younger mothers was observed for vascular disruption anomalies overall and for the individual anomalies: gastroschisis and congenital constriction bands. Conclusion: Vascular disruption anomalies that had an increased risk for younger mothers (such as gastroschisis) had a higher maternal age standardized prevalence in the United Kingdom, while vascular disruption anomalies with weaker associations with younger mothers (such as transverse limb reduction defects) did not have an increased prevalence in the United Kingdom, which may indicate a different etiology for these anomalies

Epidemiology of achondroplasia: a population-based study in Europe

Achondroplasia is a rare genetic disorder resulting in short-limb skeletal dysplasia. We present the largest European population-based epidemiological study to date using data provided by the European Surveillance of Congenital Anomalies (EUROCAT) network. All cases of achondroplasia notified to 28 EUROCAT registries (1991–2015) were included in the study. Prevalence, birth outcomes, prenatal diagnosis, associated anomalies, and the impact of paternal and maternal age on de novo achondroplasia were presented. The study population consisted of 434 achondroplasia cases with a prevalence of 3.72 per 100,000 births (95%CIs: 3.14 – 4.39). There were 350 live births, 82 terminations of pregnancy after prenatal diagnosis, and two fetal deaths. The prenatal detection rate was significantly higher in recent years (71% in 2011 – 2015 vs. 36% in 1991 – 1995). Major associated congenital anomalies were present in 10% of cases. About 20% of cases were familial. After adjusting for maternal age, fathers >34 years had a significantly higher risk of having infants with de novo achondroplasia than younger fathers. Prevalence was stable over time, but regional differences were observed. All pregnancy outcomes were included in the prevalence estimate with 80.6% being live born. The study confirmed the increased risk for older fathers of having infants with de novo achondroplasia.JRC.F.1-Health in Societ